Direkt zum Inhalt
Merck

D3821

Devazepide

≥98% (HPLC), powder

Synonym(e):

(S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide, L-364,718, MK 329

Slide 1 of 1
Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

5 MG

€ 189,00

25 MG

€ 636,65

€ 189,00

Warenkorb auf Verfügbarkeit prüfen
​
Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C25H20N4O2
CAS-Nummer:
103420-77-5
Molekulargewicht:
408.45
NACRES:
NA.77
PubChem Substance ID:
329798778
UNSPSC Code:
12352200
MDL number:
MFCD00864500
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

DMSO: >5 mg/mL

originator

Merck & Co., Inc., Kenilworth, NJ, U.S.

storage temp.

2-8°C

SMILES string

CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15

InChI

1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1

InChI key

NFHRQQKPEBFUJK-HSZRJFAPSA-N

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
SML2883SML2984SML1984
Devazepide ≥98% (HPLC), powder

D3821

Devazepide

Paquinimod ≥98% (HPLC)

Sigma-Aldrich

SML2883

Paquinimod

BIX02188 ≥98% (HPLC)

Sigma-Aldrich

SML2984

BIX02188

GSK9311 ≥98% (HPLC)

Sigma-Aldrich

SML1984

GSK9311

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

−20°C

solubility

DMSO: >5 mg/mL

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear (warmed)

storage condition

desiccated

storage condition

-

storage condition

-

storage condition

-

General description

Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone.

Application

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices.

Biochem/physiol Actions

Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.
Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.
Devazepide is a CCK1 receptor antagonist.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H300

Hazard Classifications

Acute Tox. 1 Oral

Lagerklasse

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
010M4600V
0000144613
0000144613
0000144617

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Shannon A Metcalf et al.
Peptides, 32(6), 1296-1302 (2011-05-12)
One of the possible mechanisms by which the weight-reducing surgical procedure ileal interposition (II) works is by increasing circulating levels of lower gut peptides that reduce food intake, such as glucagon like peptide-1 and peptide YY. However, since this surgery
Wenya Chen et al.
Bioscience, biotechnology, and biochemistry, 76(6), 1104-1109 (2012-07-14)
We have recently reported that oral gavage of a potato extract (Potein®) suppressed the food intake in rats. The satiating effect of the potato extract was compared in the present study to other protein sources, and the involvement of endogenous
Involvement of endogenous CCK and CCK1 receptors in colonic motor function
Varga G, et al.
British Journal of Pharmacology, 141(8), 1275-1284 (2004)
Effect of devazepide reversed antagonism of CCK-8 against morphine on electrical and mechanical activities of rat duodenum in vitro
Xu MY, et al.
World Journal of Gastroenterology, 4(6), 524-524 (1998)
Yuki Orikawa et al.
Molecular pain, 6, 72-72 (2010-10-29)
Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine prolonged the survival period in a lethal pancreatic cancer xenograft
Alle zugehörigen Dokumente anzeigen

Global Trade Item Number

SKUGTIN
D3821-5MG04061833563588
D3821-25MG04061832897813

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung